| Vaccine Therapy in Treating Patients With Metastatic Breast Cancer (NCT00071942) | National Cancer Institute (NCI) | 2003-10-01 |
| Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer (NCT00159458) | University of Southern California | 2003-07-01 |
| Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine (NCT00228358) | University of Washington | 2003-06-01 |
| Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer (NCT00045188) | National Cancer Institute (NCI) | 2002-08-01 |
| Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer (NCT00055861) | National Cancer Institute (NCI) | 2002-07-01 |
| Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer (NCT00039455) | National Cancer Institute (NCI) | 2002-04-01 |
| Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer (NCT00024154) | National Cancer Institute (NCI) | 2002-02-01 |
| Decitabine in Treating Patients With Advanced Solid Tumors (NCT00030615) | National Cancer Institute (NCI) | 2001-12-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (NCT00030498) | National Cancer Institute (NCI) | 2001-12-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (NCT00028496) | National Cancer Institute (NCI) | 2001-11-01 |
| Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors (NCT00028535) | National Cancer Institute (NCI) | 2001-11-01 |
| PS-341 in Treating Women With Metastatic Breast Cancer (NCT00025584) | National Cancer Institute (NCI) | 2001-08-01 |
| Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer (NCT00017394) | National Cancer Institute (NCI) | 2001-03-01 |
| Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer (NCT00004888) | National Cancer Institute (NCI) | 2001-01-01 |
| Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer (NCT00006228) | National Cancer Institute (NCI) | 2000-07-01 |
| Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer (NCT00005817) | National Cancer Institute (NCI) | 2000-03-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |
| Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic (NCT00003440) | National Cancer Institute (NCI) | 1998-07-01 |
| Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer (NCT00003536) | Burzynski Research Institute | |
| Antineoplaston Therapy in Treating Women With Advanced Breast Cancer (NCT00003455) | Burzynski Research Institute | |
| Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer (NCT00053339) | Alliance for Clinical Trials in Oncology | |